Identification of a Novel Biomarker for Biliary Tract Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. (14th June 2012)

• Record Type: Journal Article
• Authors: Kikkawa, Shintaro; Sogawa, Kazuyuki; Satoh, Mamoru; Umemura, Hiroshi; Kodera, Yoshio; Matsushita, Kazuyuki; Tomonaga, Takeshi; Miyazaki, Masaru; Yokosuka, Osamu; Nomura, Fumio
• Other Names: Poon Terence C. W. Academic Editor.
• Is Part Of: International journal of proteomics. Volume 2012(2012)
• Publication Date: 2012-06-14
• Subjects: Proteomics -- Periodicals; Proteomics; Proteomics; Electronic journals; Periodical; Fulltext; Internet Resources; Periodicals; Periodicals; 572.6
• DOI: 10.1155/2012/108609
• Languages: English
• ISSNs: 2090-2166

Abstract

Abstract : Early diagnosis of biliary tract cancer (BTC) is important for curative surgical resection. Current tumor markers of BTC are unsatisfactory in terms of sensitivity and specificity. In a search for novel biomarkers for BTC, serum samples obtained from 62 patients with BTC were compared with those from patients with benign biliary diseases and from healthy controls, using the MALDI-TOF/TOF ClinProt system. Initial screening and further validation identified a peak at 4204 Da with significantly greater intensity in the BTC samples. The 4204 Da peak was partially purified and identified as a fragment of prothrombin by amino acid sequencing. The sensitivity of the 4204 Da peptide for detection of stage I BTC cancer was greater than those for CEA and CA19-9. Also, serum levels of the 4204 Da peptide were above the cut-off level in 15 (79%) of 19 cases in which the CEA and CA19-9 levels were both within their cut-off values. Receiver operating characteristic analysis showed that the combination of the 4204 Da peptide and CA19-9 was significantly more sensitive for detection of stage I BTC cancer compared to CEA and CA19-9. These results suggest that this protein fragment may be a promising biomarker for biliary tract cancer.